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Abstract: The development of small molecule inhibitors of growth factor receptors, and the discovery of somatic
mutations of the thyrosine kinase domain, have resulted in new paradigms for cancer therapy. Digital microsco-
py is an important tool for surgical pathologists. The achievements in the digital pathology field have modified
the workflow of pathomorphology labs, enhanced the pathologist’s role in diagnostics, and increased their con-
tribution to personalized targeted medicine. Digital image analysis is now available in a variety of platforms to
improve quantification performance of diagnostic pathology. We here describe the state of digital microscopy as
it applies to the field of quantitative immunohistochemistry of biomarkers related to the clinical personalized
targeted therapy of breast cancer, non-small lung cancer and colorectal cancer: HER-2, EGFR, KRAS and
BRAF genes. The information is derived from the experience of the authors and a review of the literature.
(Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 4, pp. 570–578)
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Introduction
Two key technologies are transforming pathology:
digital pathology and personalized medicine. Advanc-
es in pathology and diagnostic technology, in conjunc-
tion with advances in genetics and genomics, are pro-
moting the development of personalized medicine.
In recent years, digital imaging has been applied
to many medical fields. Due to technological im-
provements of hardware and software, digital mi-
croscopy has become an important diagnostic tool
in surgical pathology. Digital microscopy creates
a digital version of whole glass slides (WSI, Whole
Slide Image), which can be dynamically viewed, nav-
igated and magnified on a monitor across a com-
puter network. Digital slides can be integrated into
existing hospital databases and accessed via intra-
net or the internet for teaching, primary diagnosis,
teleconsultation and quality assurance [1]. For many
pathologists, knowledge of digital microscopy relates
to telepathology. The introduction of high resolu-
tion and automated whole slide imaging allows pa-
thologists to share images rapidly with remote loca-
tions. Telepathology is the first area to experience
the widespread use of digital systems. Telepatholo-
gy and WSI are already impacting pathology prac-
tices. Digital images allow the performance of digi-
tal algorithms for analysis and quantification [1–7].
Software for digital image analysis has long been
used in the research setting to quantify morphomet-
ric features or the intensity of staining. Digital im-
age analysis is now available in a variety of platforms
to improve the quantification performance of diag-
nostic pathology [1, 5–7].
Personalized medicine refers to the specific de-
livery of healthcare (either preventive or therapeu-
tic) according to single or multiple genomic or mo-
lecular biomarker(s). The US Congress has attempt-
ed to define personalized medicine as: “the applica-
tion of genomic and molecular data to better target
the delivery of healthcare, facilitate the discovery and
clinical testing of new products, and help determine
a person’s predisposition to a particular disease or
condition” [8].
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The objective of personalized medicine is to iden-
tify patients at risk of illness according to their ge-
nomic profile, and to provide the proper drug at the
right dose for the right patient at the right time. Es-
sential components of personalized medicine for can-
cer patients may include the presence of disease-spe-
cific gene(s) or gene profiles that control cancer
growth, the standardization of biomarkers for identi-
fication of such a molecular target, and the applica-
tion of an effective therapy against it [9].
Immunohistochemistry (IHC) is a frontline assay
for identifying these molecules and revealing trans-
lated proteins in normal and diseased cells. IHC as
a diagnostic tool in surgical pathology has replaced oth-
er ancillary studies, and is widely applied in tumor
diagnostics, sometimes with specific IHC antibodies
for a particular type of cancer, and sometimes in dif-
ferential diagnosis which requires a panel of antibod-
ies. It has also recently been gaining ground in prog-
nostic and predictive markers for a number of differ-
ent tumors to predict response to targeted therapy.
Screening for biomarkers related to patients’ response
to molecular targeted therapy upgrades the patholo-
gist’s responsibility in therapy decisions.
Pathologists in their diagnostic processes rely on
the patient’s clinical data, results of imaging, morphol-
ogy, and various ancillary techniques such as immuno-
histochemistry, cytogenetics, and molecular diagnos-
tics. IHC has been most commonly used as a research
tool in biomedical research. A three-fold increase in
immunohistochemical studies over the last 20 years
indicates the growing popularity of IHC tests [10].
Quantification of immunostaining is a frequently
used technique in pathology. Manual quantification
of immunohistochemically stained tissue biomarkers
is laborious and subjective, and is prone to inter- and
intraobserver variability. Various discrete scoring sys-
tems, based on evaluation of the intensity and extent
of immunostaining, have been proposed to improve
reproducibility. Software for digital images analysis
has long been used in the research setting to quantify
morphometric features or intensity of staining. New
automated procedures implemented for quantitative
digital image analysis of various immunohistochemi-
cal markers are more objective and faster, and pro-
vide accurate and sensitive measurement of protein
expression within tissue specimens [1, 4, 6, 11]. How-
ever, the use of automated image analysis technology
for tissue biomarker quantification by itself can in-
troduce non-biologic variables that potentially could
bias the analysis. The threshold and cut-off values for
image acquisition and data extraction from the ac-
quired images are critical for measuring staining in-
tensity. Automated quantitative imaging systems are
sensitive to technical variables that can influence the
intensity of the immunostaining (e.g. calibration com-
pression). Strict standardization of the overall assay,
using standard operating procedures and appropriate
quantifiable reference controls, are a fundamental pre-
requisite to achieve the accurate and reliable quantifi-
cation of protein biomarkers in tissues [1, 5, 11, 12].
Most currently used automated image analysis al-
gorithms are designed to brightfield IHC in systems
based on virtual slides. The available IHC algorithms
are nuclear, membrane, cytoplasmic, rare event.
There are a number of computer-based programs
designed specifically for the quantitative analysis of
IHC such as: BLISS and IHC score from Bacus Lab-
oratories, Inc (Lombard, IL, USA); ACIS from Clar-
ient, Inc (San Juan Capistrano, CA, USA); iVision
and GenoMx from BioGenex (San Ramon, CA,
USA); ScanScope from Aperio Technologies (Vista,
CA, USA); Ariol SL-50 from Applied Imaging Cor-
poration (San Jose, CA, USA); LSC Laser Scanning
Cytometer from CompuCyte Corporation (Cam-
bridge, MA, USA); and SlidePath’s Tissue Image
Analysis and AQUA from HistoRx Inc (New Haven,
CT, USA) [4, 13]. Some of the image analysis systems
have additional options for fluorescent imaging, Flu-
orescence In Situ Hybridization (FISH), and Chro-
mogenic In Situ Hybridization (CISH). There are
other available solutions for image analysis in IHC,
which are not based on whole slide imaging of pa-
thology slides (e.g. Ventana Image Analysis System
(VIAS). Several commercial image analysis applica-
tions for IHC quantification have proved that auto-
matic quantification provides more reliable and more
uniform results than manual evaluation, and have
received clearance from the US Food and Drug Ad-
ministration (FDA) [5, 6].
The role of IHC data sets and analysis in diagnos-
tic pathology is being challenged by other quantita-
tive methods such as DNA microarray and qRT-PCR
in cancer detection, classification and predicting can-
cer treatment response [14].
Tissue Micro Arrays (TMA) applications are an-
other important tool for molecular analysis to help
identify new diagnostic and prognostic markers and
targets in human cancers. The key benefit underlying
TMA technology is the ability to assay hundreds of
patient tissues arrayed on a single microscope slide.
TMAs are ideal for efficient screening of prospective
biomarkers by a variety of different mechanisms in-
cluding IHC, FISH and RNA in situ hybridization.
Most studied biomarker assays on TMAs use immu-
nohistochemical techniques. The TMA slides can be
‘whole-slide’ imaged. This allows results of experi-
ments to be shared with other investigators. Signifi-
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cant work has been done to standardize data capture
to facilitate the subsequent exchange of information.
TMA histospots allow the assessment of tumor het-
erogeneity and provide a new opportunity for devel-
oping automated methods for TMA analysis. There
are ongoing efforts to generate software tools for
automated analysis of TMA localization data. The
advances made in automated quantitative analysis of
IHC-TMAs play an important role in defining pre-
dictive biomarkers for future biospecific therapies
[15–18]. Several experiences of TMA analyses using
virtual slides have been reported. Currently available
TMA scoring image analysis systems include:
3DHistech Mirax TMA, Alphelys Spot Browser® 3,
Aperio TMALab™ II, Bacus TMAscore, Dako
ACIS® IIITissue Micro-Array, Definiens TissueMap,
and SlidePath OpTMA [1, 4].
Multispectral imaging is becoming important in
immunohistochemistry analysis. This technique of
multiplexing capacity allows immixing of three or
more chromogens in multicolor IHC [19].
Personalized targeted therapy
Personalized medicine is an initiative to treat each
patient as an individual. In recent years, targeted
therapies for a variety of malignant tumors have
achieved clinically significant response rates and
have enabled oncologists to develop individual-based
therapy strategies for patients. It has been demon-
strated on a large scale that the personalized medi-
cine approach is associated with improved clinical
outcomes [20–25]. The rationale for such therapeu-
tic approaches is the identification of the targeted
molecule in the tumor of the patient to be treated.
Especially for solid malignant tumors, a growing list
of target molecules is now routinely estimated by
IHC staining in biopsy specimens and surgically re-
moved tumor material, generating important data
for therapeutic decisions and prognostically relevant
information [25].
The identification of patients who may benefit
from targeted approaches demands accurate assays
for the biomarkers determining optimal treatment.
Currently proposed biomarkers help in early cancer
detection or selecting cancer patients for treatment.
They have also built a base in diagnostics and pre-
dicting biological pathways of cancers. There are 286
known tumor suppressing genes, and 33 known on-
cogenes, many of which are being actively targeted
by drug companies. However, there are only five
well-documented cancer drugs targeting the genes:
HER-2/neu, EGFR (Epidermal Growth Factor
Receptors), KRAS, BRAF (proto-oncogene B-Raf),
and the adenomatous polyposis coli (APC) gene.
The biomarkers can be detected by immunohis-
tochemical methods, quantitative proteomic methods,
and methods such as quantitative real-time poly-
merase chain reaction (qRT-PCR) [26]. The promo-
tion of molecular and individualized medicine is based
on the improvement and miniaturization of methods
of proteomics and genomics in the search for biom-
arkers of disease onset, progression and treatment
response [27]. In the pathology labs, the main tech-
niques used to analyze the tumor tissue for specific
genetic/molecular aberrations are: *Polymerase Chain
Reaction (PCR)-based sequencing for the molecular
composition, *immunohistochemistry for revealing
cells translated proteins (a frontline assay), and FISH
for genetic composition.
Immunohistochemistry is the commonest screen-
ing strategy for evaluating most studied biomarkers
in the pathology labs, e.g. for Her-2, estrogen recep-
tors (ER) and progesterone receptors (PR), EGFR.
IHC has encountered problems of reproducibility
and lack of standardization, resulting in poor con-
cordance between laboratories. Different labs use
different IHC reagents and kits with different stain-
ing characteristics; they also have slightly different
IHC staining processes, different scoring schemes
for nuclear stains, and different cut-off thresholds.
The reproducibility of IHC stains is important for
consistent algorithm performance. For this reason,
it is recommended to use FDA-approved IHC kits
and to employ appropriate morphological studies
and controls as specified in the instructions for the
IHC kits [21–23, 28–30]. Clinical assays to assess
cancer biomarkers include IHC status for the de-
tection of protein over-expression, and/or gene
amplification by fluorescence in situ hybridization,
with validated clinical trials having gained FDA
approval. To help pathologists, specific algorithms
for cell membrane immunoreactions, mainly of
HER2 protein detection, and for nuclear signal
detection, especially of ER/PR, have been devel-
oped for the automated classification of breast
cancers and predicting their potential response to
immuno- or hormone therapy, respectively. Vari-
ous integrated scanning and image analysis systems
are available for automated examination of immu-
nohistochemistry and FISH signals; some are based
on virtual slides or WSI, offering options of remote
IHC analysis [1–7, 18, 19]. Many studies have fo-
cused on variables related to the automated image
analysis in immunohistochemistry and virtual mi-
croscopy [12, 18, 31–34]. Several software devel-
opers have applied for and received FDA approval
for digital-assisted analysis of HER2 staining and
other stains including estrogen receptor and proges-
terone receptor [5, 6].
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Human Epidermal Growth Factor Receptor 2
(HER-2)
The HER family of transmembrane receptors con-
sists of four related members: Her-1 (also known as
epidermal growth factor receptor (EGFR), HER-2,
HER-3, and HER-4. They consist of an extracellular
ligand binding domain, a transmembrane domain, and
an intracellular tyrosine kinase domain. HER2 over-
expression by gene amplification occurs in approxi-
mately 20% of breast cancers and is associated with
aggressive biology and poor prognosis of resected and
metastatic tumors. HER2 status has been shown to
be predictive for response to certain chemotherapeu-
tic agents. Overexpression of HER1 is found in about
40% of breast cancers and also portends a poor prog-
nosis in breast cancer. Overexpression of either HER1
or HER2 is associated with relative resistance to en-
docrine therapy [35, 36].
The assessment of HER2 in invasive breast can-
cer has been mandatory for treatment decisions since
the advent of targeted therapy with the recombinant
humanized IgG monoclonal antibody trastuzumab
(Herceptin®, Genentech, Inc., South San Francisco,
CA, USA; Hoffmann-La Roche Ltd., Basel, Switzer-
land) and the small molecule dual HER1/HER2 ty-
rosine kinase inhibitor lapatinib (Tykerb, GlaxoSmith-
Kline, Philadelphia, PA, USA) [22, 28, 30, 37]. Screen-
ing of newly diagnosed breast carcinomas is mostly
performed by IHC. A typical immunohistochemical
panel provided in the pathological assessment of
breast cancer includes HER-2 and ER/PR stains per-
formed by IHC validated assays [19, 21].
The American Society of Clinical Oncology
(ASCO) and the College of American Pathologists
(CAP), in their joint guidelines for the laboratory
evaluation of HER-2 status, describe in detail the
methodological requirements for IHC and FISH anal-
yses [23, 26, 30]. An objective, reproducible technique
for HER2 and ER/PR interpretation is particularly valu-
able, since the result leads to an important treatment
decision. HER-2 is a membrane stain evaluated by its
intensity and completeness of the membrane staining
according to the recommended scoring method. Pathol-
ogists may use a semi-quantitative or automated meth-
od to determine protein expression [5, 31–34].
Breast cancer specimens with equivocal immuno-
histochemistry undergo validation using a Her-2 gene
amplification method called Fluorescence In Situ
Hybridization. FISH testing is a far more quantita-
tive and reproducible method, as it directly measures
the number of copies of the HER2 gene. However,
FISH testing is associated with greater cost and takes
more time than an analysis employing immunohis-
tochemistry [38]. Newer methodologies for establish-
ing Her-2 status including RT-PCR and CISH have
not yet been validated.
The IHC Image Analysis algorithms for automat-
ed assessment of HER-e and ER/PR (with FDA
Clearance: Aperio and ACIS III) can be used as an
aid to pathologists for the assessment of stained breast
tissue slides [5, 6]. Additionally, the Aperio system of-
fers an option for remote IHC quantitative analysis of
HER-2 and/or ER/PR in virtual slides or WSIs [5].
Estrogen receptors and progesterone receptors
Today, immunohistochemistry is accepted as the stan-
dard evaluation method for determining ER and PgR
status. The increased sensitivity depends mainly on
the pretreatment and detection systems. CAP/ASCO
have developed and published joint guidelines aimed
at improving the accuracy of immunohistochemical
ER/PgR testing in breast cancer [21]. These guide-
lines describe validation procedures for ER and PgR
IHC assays that are used to predict response to tamox-
ifen and aromatase inhibitors (predictive markers).
IHC validation, additional quality control and assur-
ance measures are important new requirements of the
ASCO–CAP guidelines. As with all IHC studies of
therapeutic targets, accurate and quantitative assess-
ments of the results are critical. Several major factors
can dramatically affect the apparent ER and PR sta-
tus of the breast cancer as determined by IHC, in-
cluding: tissue fixation, choice of anti-ER or anti-PR
antibody, manual vs. automated staining platforms,
and the determination of thresholds for reporting
positive results. Improving the quality of IHC assays
on a global scale requires that all laboratories imple-
ment standardized and validated assays recommend-
ed by CAP/ASCO for ER and PR testing [21, 29].
Some studies have suggested that although IHC per-
formed on TMAs can closely approximate the results
obtained by evaluating much larger tissue sections,
they are still unlikely to account for all the heteroge-
neity, and TMAs are not used in routine clinical prac-
tice. It is unrealistic to expect that even perfect tests
for ER and PR alone, regardless of the technology,
will be sufficiently powerful to accurately predict the
response of all patients, because the biology is so com-
plex. New, more powerful predictors are needed, and
are being investigated. They will most likely be based
on multiple biomarkers [39].
Automated microscopy and computerized pro-
cessing have provided increased accuracy in quantifi-
cation and standardization. A number of groups have
published data on the automated assessment of the
ER/PR in breast cancer [34, 40–43] describing an ex-
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cellent correlation between manual and automated
analysis. Various automated image analysis systems
offer a possibility of rapid and objective scoring of
immunostained nuclei (IHC Nuclear Image Analysis
algorithms), but only a few have received FDA ap-
proval [5, 6]. Although IHC test methods have im-
proved with the widespread adoption of automated
staining platforms, the laboratories with assays cleared
or approved by the FDA must verify the performance
specifications stated by the manufacturer.
Ki-67 — a cell proliferated associated nuclear an-
tigen, is another prognostic marker supplemented the
breast cancer characteristics. The Ki-67 status is re-
ported as a percentage of invasive carcinoma cells
exhibiting positive nuclear staining: less than 10% (fa-
vorable prognosis); more than 20% (unfavorable
prognosis); and 10% to 20% (borderline category).
The Ki-67 growth fraction is significantly related to
the grade in most tumors, being the highest in grade 3
invasive carcinomas. ER- and PR-negative tumors
tend to have a high Ki-67 proliferation index. The
microscopic quantitation of Ki-67 Labelling Index
(Ki-67 LI) by the IHC method is available via com-
mercial computerised algorithms based on digital mi-
croscopy or WSIs.
Epidermal growth factor receptor
(EGFR; HER1, erbB-1)
Epidermal growth factor receptors are among the
most studied cancer biomarkers because of their on-
cogenic activity in diverse tumor types. EGFR is highly
expressed in a variety of solid malignant tumors and
its expression has been correlated with disease pro-
gression and poor survival. EGFR recently has attract-
ed clinical attention because of the development of
targeted therapies. There are two classes of anti-EGFR
agents — monoclonal anti-EGFR antibodies and
small-molecule EGFR TKIs — currently used in
EGFR-targeted therapy [24]. Therapies based on mon-
oclonal antibodies (MAbs) such as IMC-C225 (cetux-
imab) have been tested in clinical trials on patients with
head and neck cancer, colon cancer, pancreatic can-
cer, and non-small-cell lung cancer (NSCLC) [25].
EGFR in NSCLC
Identification of the relevant molecular subtypes of
this heterogeneous disease and selecting patients for
the appropriate targeting agents is critical in the per-
sonalized therapy of NSCLC. Two classes of anti-EGF
receptor (EGFR) agents, monoclonal anti-EGFR
antibodies and small-molecule EGFR tyrosine kinase
inhibitors, have been used for the treatment of
NSCLC (24). The clinical guidelines for NSCLC have
been changed to incorporate genetic testing for
EGFR mutations to identify patients who would ben-
efit from targeted oral therapy with erlotinib or gefi-
tinib instead of chemotherapy. EGFR inhibitors such
as erlotinib (Tarceva, Genentech/OSI Pharmaceuti-
cals) are now considered the best treatment option
for patients with NSCLC whose tumors harbor EGFR
mutations. It has been documented that EGFR mu-
tations are related to lung cancer histology. Lung ad-
enocarcinomas frequently possess EGFR mutations
and frequently exhibit increased EGFR copy num-
ber [44]. In the United States, approximately 15% of
patients with adenocarcinoma of the lung harbor ac-
tivating EGFR mutations. The majority of these mu-
tations are in exons 19 and 21 of the EGFR gene [22].
EGFR mutations are present in adenocarcinomas in
about 10% of Western patients and in about 50% of
Asian patients, most frequently in women, non-smok-
ers, and non-mucinous tumors [45, 46]. Large-cell
carcinoma harbors EGFR mutations very rarely.
EGFR mutations have been found particularly fre-
quently in adenocarcinomas of the papillary subtype
[47]. It appears that EGFR mutations occur much
less frequently in squamous cell carcinoma than in
adenocarcinoma, with a reported incidence of 0–14%
[45, 48]. In the setting of recurrent and metastatic
disease of lung cancer, EGFR testing is a recommen-
dation for three histological types: adenocarcinoma,
large cell carcinoma, and NSCLC not otherwise spec-
ified. Erlotinib is recommended as the first-line sys-
temic therapy in patients with these three relevant
histological subtypes and a positive EGFR mutation.
Due to the ongoing revolution in the treatment of
lung cancer, pathomorphological reporting has an-
other value. The microscopic evaluation of the histo-
logic subtype of NSCLC has become important in
tumor selection for EGFR testing.
With the advent of targeted therapies, there has
been an increasing interest in IHC based EGFR
screening methods using paraffin-embedded tumor
specimens to select cancer patients eligible for treat-
ment with cetuximab [25, 49–51]. The interpretation
of immunohistochemical results relies on subjective
judgment. With EGFR, distinct membranous stain-
ing of tumor cells is considered as a positive immu-
noreaction. Various IHC scores have been used for
manual evaluation of EGFR immunoexpression
[49, 50]. Only limited studies have analyzed the crite-
ria needed to define a positive immunoreaction for
EGFR [51]. Although digital pathology offers an op-
tion of computerized quantitative analysis for EGFR
expression by IHC algorithm for membrane staining
[4–6], the results of the clinical implications of EGFR
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overexpression have been inconclusive thus far. Im-
munohistochemistry-based assays measuring EGFR
expression cannot reliably predict the response to
EGFR TKI therapy. Clinical studies have been un-
able to demonstrate a distinct correlation between
EGFR expression and the likelihood of response to
EGFR inhibition with targeted antibodies [52, 53].
Since the use of EGFR overexpression as a prognos-
tic marker has largely been unproductive, consider-
able efforts have been made to develop antibodies
that react specifically with the mutant form of EGFR.
The detection of mutant EGFR by these two anti-
bodies has been performed by Western blotting, im-
munofluorescence and IHC [54].
In the published provisional clinical opinion of
ASCO on mutation testing for advanced NSCLC —
at the time of publication, there was no FDA-cleared
test for the EGFR mutation. Fluorescent in situ hy-
bridization and immunohistochemistry testing for
EGFR at the present time are not recommended for
the purposes of treatment decisions because they do
not reproducibly predict outcome [22]. The most com-
monly used methods to detect mutations are direct
sequencing and real-time PCR.
KRAS oncogene
The KRAS oncogene (the cellular homolog of the
Kirsten rat sarcoma virus gene) is a critical gene in
the development of a variety of cancers. Mutations in
the KRAS gene are common in many types of can-
cer, including pancreatic cancer (~65%), colorectal
adenomas (30%), colorectal cancer (30% to 50%),
lung cancer (~20%) and ovarian cancer (~15%)
[55, 56]. KRAS mutation status has great value in as-
sisting therapy decisions. Mutations in critical areas of
the KRAS gene, such as codons 12 and 13, are a neg-
ative predictor of response to anti-EGF receptor an-
tibodies in colorectal cancer, and similarly are indi-
cators of resistance to small-molecule tyrosine kinase
inhibitors in NSCLC patients. KRAS mutation status
is determined by many methods, including allele-spe-
cific PCR, real-time PCR methods and nucleic acid
sequencing techniques in tumor samples. Patients with
colorectal cancer and with KRAS mutations do not
respond to treatment with vectibix (Amgen) or cetux-
imab (Erbitux, Bristol-Myers Squibb) — the antibod-
ies that inhibit EGFR [57, 58]. The pathologist’s role
is to assess tumor histology and KRAS mutation sta-
tus prior to the therapeutic decision concerning the
use of an EGFR inhibitor [59]. Also, ASCO supports
KRAS gene mutation testing before the initiation of
EGFR inhibitors in patients with metastatic colorec-
tal cancer [60].
Adenomatous Polyposis Coli (APC) gene
The APC suppressor gene is mutated in most colorec-
tal cancers [61]. The protein made by the APC gene
plays a critical role in several cellular processes that
determine whether a cell may develop into a tumor.
Approximately 3–5% of colon cancers are associated
with high-risk, inherited colon cancer syndromes.
Familial Adenomatous Polyposis (FAP) is an autoso-
mal-dominant syndrome that accounts for < 1% of
all colorectal cancers. More than 90% of families af-
fected by FAP, or an FAP variant, have a mutation in
APC, which encodes the tumor suppressor APC —
a key molecule in several intracellular pathways
[61–63]. Genetic testing for FAP typically involves
DNA sequencing, often preceded by complementary
methods which correctly identify up to 95% of muta-
tions [63].
BRAF gene
BRAF is a serine/threonine protein kinase, encoded
on chromosome 7q34, that activates the MAP kinase/
/ERK-signaling pathway. More than 30 mutations of
the BRAF gene associated with human cancers have
been identified. The frequency of BRAF mutations
varies widely in human cancers from more than 80%
in melanomas and nevi, to as little as 0–18% in other
tumors, such as 1–3% in lung cancers and 5% in col-
orectal cancer. Approximately 42% of melanomas
harbor activating BRAF mutations. The commonest
mutations are V600E and V600K. The development
of targeted therapies for malignant melanoma has
occurred rapidly, from the discovery of the target to
drug development. We have been able to give suffi-
cient drugs to block mutated BRAF, resulting in clin-
ical benefit for a majority of patients treated at high-
er doses. PLX4032 is important because it represents
an advance in targeting BRAF; it suppresses the acti-
vated oncogenic pathway by inhibiting the ERK ki-
nase cascade. High objective response rates were ob-
served in the phase I clinical trial of PLX4032 in
a cohort of melanoma patients selected for tumors with
the V600E mutation. Ongoing phase II and phase III
clinical trials are limited to those patients with BRAF
V600E mutations [64–66]. Recently, the results of
a phase III randomized clinical trial comparing BRAF
inhibitor vemurafenib with chemotherapeutic agent
dacarbazine in patients with previously untreated
metastatic melanoma with the BRAF V600E muta-
tion was reported [67]. Although many patients have
tumor regression, the majority of patients treated
with BRAF inhibitors develop secondary resistance
and subsequent disease progression. Thus these de-
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velopments in melanoma not only validate the con-
cept of personalized cancer therapy, but also high-
light the need to serially characterize tumors in or-
der to understand the mechanisms leading to ac-
quired resistance and to develop rational combina-
torial therapies [67].
Conclusions
Personalized medicine represents the future due to
better understanding of the unique genetic charac-
teristics of tumors and their metabolic pathways. The
great achievements noted in developing new drugs
against cancers with a specific genetic composition
can efficiently interrupt pathways of some organ-spe-
cific tumor cells. Molecular profiling and driver mu-
tations of the cancers need more accurate diagnostic
and molecular tests in the pathology labs. The use of
powerful computer technology and digital microsco-
py has the potential to upgrade the pathologist’s con-
tribution in the successful development of personal-
ized targeted therapy.
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